• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Analysis of molecular mechanisms of CCHFV cell entry and the pathogenicity

Research Project

Project/Area Number 20K07516
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 49060:Virology-related
Research InstitutionNagasaki University

Principal Investigator

Sakurai Yasuteru  長崎大学, 熱帯医学研究所, 助教 (00818338)

Project Period (FY) 2020-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2022: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Keywordsクリミア・コンゴ出血熱ウイルス / 細胞侵入過程 / 病原性発現機序 / 膜融合 / 侵入阻害剤 / CCHFV / シュードタイプウイルス / 複数のウイルス株 / 宿主細胞侵入 / 抗血清 / ダニ / シュードウイルス / 表面糖タンパク質 / 病原性 / 治療標的
Outline of Research at the Start

クリミア・コンゴ出血熱ウイルス(CCHFV)は、ヒトに重篤な疾患を引き起こす病原体であるが、その病原性発現機序は未解明な部分が多い。また、CCHFVは株間でヒトへの病原性の違いがあることが報告されているが、その要因も分かっていない。そこで本研究では、最近我々が開発したCCHFV由来のシュードウイルスを用いて、種々のウイルス株由来の表面糖タンパク質依存的な細胞侵入過程を比較解析し、その感染過程を要因とする病原性発現機序の解明を目指す。更に、その感染メカニズムを標的とした治療薬候補の探索も行う。

Outline of Final Research Achievements

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus, which causes a severe infectious disease in human. The detailed molecular mechanisms of viral replication and pathogenicity as well as the difference between virus strains are still largely unknown.
In this study, we successfully produced pseudotyped virus bearing glycoproteins of multiple CCHFV strains and developed a quantitative assay for membrane fusion. These experimental tools can be useful for detailed and comparative analyses of CCHFV cell entry steps.
Moreover, using the newly-developed assays, pan-nairovirus fusion inhibitors were identified among FDA-approved drugs. Different sensitivities to neutralizing antibodies and external stimulus between viruses were also demonstrated. We expect that these results will contribute to development of antiviral therapy and disinfection method for CCHFV.

Academic Significance and Societal Importance of the Research Achievements

野生型CCHFVはバイオセーフティーレベル4(BSL4)施設にて扱う必要があり、限られた研究者が限られた手法でしか研究出来ない。本研究で開発したシュードタイプウイルスや膜融合アッセイを用いることで、BSL-2実験室において細胞侵入過程の多面的な解析や、ウイルス株間での相違についての詳細な解析が可能となる。更に、本研究により中和抗体や外的刺激に対する特徴的な感受性が明らかになったことで、表面糖タンパク質を標的とした治療法やウイルス不活化方法の開発がより一層進むことも期待される。

Report

(5 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (22 results)

All 2023 2022 2021 2020 Other

All Int'l Joint Research (10 results) Journal Article (6 results) (of which Int'l Joint Research: 2 results,  Peer Reviewed: 6 results,  Open Access: 5 results) Presentation (4 results) Patent(Industrial Property Rights) (2 results)

  • [Int'l Joint Research] Boston University(米国)

    • Related Report
      2023 Annual Research Report
  • [Int'l Joint Research] UK Health Security Agency(英国)

    • Related Report
      2023 Annual Research Report
  • [Int'l Joint Research] Friedrich-Loeffler-Institut(ドイツ)

    • Related Report
      2023 Annual Research Report
  • [Int'l Joint Research] Boston University(米国)

    • Related Report
      2022 Research-status Report
  • [Int'l Joint Research] Public Health England(英国)

    • Related Report
      2022 Research-status Report
  • [Int'l Joint Research] Friedrich-Loeffler-Institut(ドイツ)

    • Related Report
      2022 Research-status Report
  • [Int'l Joint Research] ボストン大学(米国)

    • Related Report
      2021 Research-status Report
  • [Int'l Joint Research] イギリス公衆衛生庁/ロンドン大学衛生熱帯医学大学院/リバプール大学(英国)

    • Related Report
      2021 Research-status Report
  • [Int'l Joint Research] Boston University(米国)

    • Related Report
      2020 Research-status Report
  • [Int'l Joint Research] Friedrich-Loeffler-Institut(ドイツ)

    • Related Report
      2020 Research-status Report
  • [Journal Article] A screen of FDA-approved drugs with minigenome identified tigecycline as an antiviral targeting nucleoprotein of Crimean-Congo hemorrhagic fever virus.2022

    • Author(s)
      Hirano M, Sakurai Y, Urata S, Kurosaki Y, Yasuda J, Yoshii K
    • Journal Title

      Antiviral research

      Volume: - Pages: 105276-105276

    • DOI

      10.1016/j.antiviral.2022.105276

    • Related Report
      2022 Research-status Report 2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases2022

    • Author(s)
      Afowowe Tosin Oladipo、Sakurai Yasuteru、Urata Shuzo、Zadeh Vahid Rajabali、Yasuda Jiro
    • Journal Title

      Viruses

      Volume: 15 Issue: 1 Pages: 105-105

    • DOI

      10.3390/v15010105

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Ebola Virus GP Activates Endothelial Cells via Host Cytoskeletal Signaling Factors2022

    • Author(s)
      Moni Benedicte Mpia、Sakurai Yasuteru、Yasuda Jiro
    • Journal Title

      Viruses

      Volume: 14 Issue: 1 Pages: 142-142

    • DOI

      10.3390/v14010142

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Identification of novel chemical compounds targeting filovirus VP40-mediated particle production2022

    • Author(s)
      Urata Shuzo、Omotuyi Olaposi Idowu、Izumisawa Ayako、Ishikawa Takeshi、Mizuta Satoshi、Sakurai Yasuteru、Mizutani Tatsuaki、Ueda Hiroshi、Tanaka Yoshimasa、Yasuda Jiro
    • Journal Title

      Antiviral Research

      Volume: 199 Pages: 105267-105267

    • DOI

      10.1016/j.antiviral.2022.105267

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] iPSC screening for drug repurposing identifies anti‐RNA virus agents modulating host cell susceptibility2021

    • Author(s)
      Imamura Keiko、Sakurai Yasuteru、Enami Takako、Shibukawa Ran、Nishi Yohei、Ohta Akira、Shu Tsugumine、Kawaguchi Jitsutaro、Okada Sayaka、Hoenen Thomas、Yasuda Jiro、Inoue Haruhisa
    • Journal Title

      FEBS Open Bio

      Volume: in press Issue: 5 Pages: 1452-1464

    • DOI

      10.1002/2211-5463.13153

    • NAID

      120007026449

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro2021

    • Author(s)
      Sakurai Yasuteru、Ngwe Tun Mya Myat、Kurosaki Yohei、Sakura Takaya、Inaoka Daniel Ken、Fujine Kiyotaka、Kita Kiyoshi、Morita Kouichi、Yasuda Jiro
    • Journal Title

      Biochemical and Biophysical Research Communications

      Volume: 545 Pages: 203-207

    • DOI

      10.1016/j.bbrc.2021.01.091

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] ミトコンドリア関連薬剤MA-5とその誘導体はSARS-CoV-2やその他RNAウイルスの感染を抑制する2023

    • Author(s)
      櫻井康晃
    • Organizer
      第70回日本ウイルス学会学術集会
    • Related Report
      2023 Annual Research Report
  • [Presentation] クリミア・コンゴ出血熱ウイルスの細胞侵入過程評価系の開発と新規侵入阻害剤の同定2022

    • Author(s)
      櫻井 康晃
    • Organizer
      第63回日本熱帯医学会大会
    • Related Report
      2022 Research-status Report
  • [Presentation] ペプチド模倣技術を用いたエボラ出血熱治療薬候補の開発2022

    • Author(s)
      櫻井 康晃
    • Organizer
      第69回日本ウイルス学会学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] Development of an efficient entry assay for Crimean-Congo hemorrhagic fever virus to identify novel entry inhibitors2021

    • Author(s)
      Yasuteru Sakurai
    • Organizer
      第68回日本ウイルス学会学術集会
    • Related Report
      2021 Research-status Report
  • [Patent(Industrial Property Rights)] 抗ウイルス剤2022

    • Inventor(s)
      阿部 高明、安田 二朗、櫻井 康晃
    • Industrial Property Rights Holder
      阿部 高明、安田 二朗、櫻井 康晃
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2022-094545
    • Filing Date
      2022
    • Related Report
      2022 Research-status Report
  • [Patent(Industrial Property Rights)] 新型コロナウイルス感染症(COVID-19)を治療及び/又は予防する方法、医薬2020

    • Inventor(s)
      北潔、森田公一、安田二朗、櫻井康晃、他4名
    • Industrial Property Rights Holder
      北潔、森田公一、安田二朗、櫻井康晃、他4名
    • Industrial Property Rights Type
      特許
    • Filing Date
      2020
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi